1418205-77-2
1418205-77-2 structure
- Name: Bimekizumab
- Chemical Name: Bimekizumab
- CAS Number: 1418205-77-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2023-02-26 12:51:54
- Modify Date: 2024-01-29 11:18:57
-
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].
| Name | Bimekizumab |
|---|
| Description | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-17A IL-17F |
| In Vitro | Bimekizumab (10 μg/mL; 1 h) results dual neutralisation of IL-17A and IL-17F, leads to osteocommitment of hPDCs by AS serum is suppressed[1]. |
| References |
| No Any Chemical & Physical Properties |